Literature DB >> 9537433

Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma.

Y Ito1, Y Sasaki, M Horimoto, S Wada, Y Tanaka, A Kasahara, T Ueki, T Hirano, H Yamamoto, J Fujimoto, E Okamoto, N Hayashi, M Hori.   

Abstract

Mitogen-activated protein kinase/extracellular signal-regulated protein kinase (MAPK/ERK) is a key molecule in intracellular signal transducing pathways that transport extracellular stimuli from cell surface to nuclei. MAPK/ERK has been revealed to be involved in the physiological proliferation of mammalian cells and also to potentiate them to transform. However, its role in the outgrowth of human hepatocellular carcinoma (HCC) has yet to be clarified. Therefore, in this study, we investigated the activation of MAPK/ERK and its associated gene expression in HCC. MAPK/ERK was activated in 15 of 26 cases of HCC we examined (58%), and its activity level was significantly higher in HCC than in the adjacent non-cancerous lesions. Besides, MAPK/ERK activation in HCC was positively correlated with protein expression of transcription factor c-Fos. Furthermore, in 25 of 26 cases of HCC which genomic DNA was available, 22 cases without genomic DNA amplification exhibited positive correlation, not only between protein expression of c-Fos and cyclin D1, but also between MAPK/ERK activation and cyclin D1 expression. Concerning the relationship between MAPK/ERK activation and the clinicohistopathological features of HCC, the tumor (HCC) versus non-tumor (non-cancerous counterpart) ratio (T/N) of MAPK/ERK activity was positively correlated with tumor size, but neither with the stage of HCC nor the degree of differentiation of HCC. In conclusion, these findings suggest that MAPK/ERK activation in human HCC may play an important role in multistep hepatocarcinogenesis, especially in the progression of HCC; at least in part, through cyclin D1 up-regulation primarily induced by MAPK/ERK via c-Fos.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9537433     DOI: 10.1002/hep.510270409

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  110 in total

1.  The mitogen-activated protein kinase kinase/extracellular signal-regulated kinase cascade activation is a key signalling pathway involved in the regulation of G(1) phase progression in proliferating hepatocytes.

Authors:  H Talarmin; C Rescan; S Cariou; D Glaise; G Zanninelli; M Bilodeau; P Loyer; C Guguen-Guillouzo; G Baffet
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

2.  Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma.

Authors:  Bert H O'Neil; Laura W Goff; John Sae Wook Kauh; Jonathan R Strosberg; Tanios S Bekaii-Saab; Ruey-Min Lee; Aslamuzzaman Kazi; Dominic T Moore; Maria Learoyd; Richard M Lush; Said M Sebti; Daniel M Sullivan
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

3.  Effect of hepatitis C virus nonstructural protein NS3 on proliferation and MAPK phosphorylation of normal hepatocyte line.

Authors:  De-Yun Feng; Yi Sun; Rui-Xue Cheng; Xiao-Ming Ouyang; Hui Zheng
Journal:  World J Gastroenterol       Date:  2005-04-14       Impact factor: 5.742

Review 4.  Does oxidative stress participate in the development of hepatocellular carcinoma?

Authors:  Yutaka Sasaki
Journal:  J Gastroenterol       Date:  2007-02-06       Impact factor: 7.527

5.  Chemotherapy agents: a primer for the interventional radiologist.

Authors:  Frank Mihlon; Charles E Ray; Wells Messersmith
Journal:  Semin Intervent Radiol       Date:  2010-12       Impact factor: 1.513

6.  Systemic Treatment of Advanced Hepatocellular Carcinoma in Older Adults.

Authors:  Luisa M Arellano; Sukeshi Patel Arora
Journal:  J Nat Sci       Date:  2018-08

7.  Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.

Authors:  Roberta Schmieder; Florian Puehler; Roland Neuhaus; Maria Kissel; Alex A Adjei; Jeffrey N Miner; Dominik Mumberg; Karl Ziegelbauer; Arne Scholz
Journal:  Neoplasia       Date:  2013-10       Impact factor: 5.715

8.  Immunohistochemical analysis of p53, cyclinD1, RB1, c-fos and N-ras gene expression in hepatocellular carcinoma in Iran.

Authors:  S J Moghaddam; E N Haghighi; S Samiee; N Shahid; A R Keramati; S Dadgar; M R Zali
Journal:  World J Gastroenterol       Date:  2007-01-28       Impact factor: 5.742

Review 9.  Immunobiology of hepatocarcinogenesis: Ways to go or almost there?

Authors:  Pavan Patel; Steven E Schutzer; Nikolaos Pyrsopoulos
Journal:  World J Gastrointest Pathophysiol       Date:  2016-08-15

Review 10.  Molecular targeted therapy for hepatocellular carcinoma.

Authors:  Melanie Thomas
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.